军事知识服务平台
CD278/PD-1双阳性表达在血管免疫母细胞性T细胞淋巴瘤诊断中的应用
Application of the CD278 and PD-1 dual-positive expression pattern in the diagnosis of angioimmunoblastic T-cell lymphoma
摘要 目的:探讨CD278与程序性死亡受体1(PD-1)双阳性表达在血管免疫母细胞性T细胞淋巴瘤(AITL)诊断中的应用价值。方法:回顾性分析2024年1月11日至2025年3月15日江苏省人民医院收治的52例经病理活检确诊的AITL患者,收集骨髓和(或)外周血样本。其中男40例,女12例,年龄66(61,71)岁;同时纳入40名健康体检者作为对照组,其中男24例,女16例,年龄59(47,62)岁。采用多参数流式细胞术(FCM),使用包含CD45、CD3、CD4、CD5、CD7、CD10、CD2、CD278及PD-1的9色抗体组合,结合前向散射光(FSC)与侧向散射光(SSC),按照目标淋巴细胞的设门顺序,分析CD4+T细胞免疫表型。以CD278与PD-1双阳性表达≥20%作为阳性判断标准,比较AITL患者与对照组间的表达差异。采用受试者工作特征(ROC)曲线及曲线下面积(AUC)评价单项及联合标志物识别肿瘤性T细胞的效能。结果:52例AITL患者中,73.1%(38/52例)检出CD4+T细胞免疫表型异常,其中94.7%(36/38)出现CD3表达缺失,与对照组(0/40)相比差异有统计学意义( P<0.001)。38例异常CD4+T细胞均表达CD5和CD45。其中,94.7%(36/38)的异常CD4+T细胞呈现CD278与PD-1双阳性表达,而对照组中未检测到此类表达(0/40),差异有统计学意义( P<0.001)。以骨髓和(或)外周血检出 CD278/PD-1双阳性异常 CD4+T 细胞作为识别肿瘤性T细胞的指标,该组合指标敏感度为 69.2%(36/52),特异度为 100%(40/40)。ROC曲线分析结果显示,CD278 联合 PD-1 检测的 AUC 为0.974(95%CI 0.932~1.000, P<0.001),优于单项PD-1检测(AUC=0.699,95% CI 0.581~0.816, P=0.002)。 结论:CD278/PD-1双阳性表达可作为识别AITL淋巴瘤细胞的重要免疫标志,可检出骨髓和外周血中比例较低的AITL细胞。
Abstract:
Objective:To investigate the application value of CD278 combined with programmed cell death protein-1 (PD-1) double positive expression in identifying neoplastic T cells in angioimmunoblastic T-cell lymphoma (AITL).Methods:A retrospective analysis was performed on bone marrow and/or peripheral blood samples from 52 pathologically confirmed AITL patients admitted to Jiangsu Provincial Hospital between January 11, 2024 and March 15, 2025. Among the patients, there were 40 males and 12 females, with a median age of 66 (61, 71) years old. Meanwhile, 40 healthy subjects receiving physical examination were enrolled as the control group, including 24 males and 16 females, with a median age of 59(47, 62) years. Multiparameter flow cytometry (FCM) was performed using a 9-color antibody panel comprising CD45, CD3, CD4, CD5, CD7, CD10, CD2, CD278, and PD-1. Combined with forward scatter (FSC) and side scatter (SSC), the immunophenotype of CD4+T cells was analyzed according to the gating strategy for target lymphocytes. The cut-off value of CD278+PD-1+ expression ≥20% was defined as positive criterion. Evaluating the efficacy of single and combined biomarkers in identifying tumor T cells using receiver operating characteristic (ROC) curves and area under the curve (AUC) .Results:Abnormal immunophenotypic CD4+ T cells were detected in 73.1% (38/52 cases) of 52 AITL patients, among which 94.7% (36/38 cases) exhibited CD3 downregulation, with statistically significant difference compared with the control group (0/40 cases, P<0.001). All 38 cases of abnormal CD4+ T cells expressed CD5 and CD45. Of these abnormal cells, 94.7% (36/38 cases) showed CD278 and PD-1 double positive expression, whereas no such population was identified in the control group (0/40 cases, P<0.001). Using the detection of CD278+PD-1+ abnormal CD4+ T cells in bone marrow and/or peripheral blood as an indicator to identify neoplastic T cells, the sensitivity and specificity were 69.2% (36/52 cases) and 100% (40/40 cases), respectively. ROC curve analysis revealed that the area under curve (AUC) of combined CD278 and PD-1 detection was 0.974 (95% CI 0.932-1.000, P<0.001), which was significantly higher than single PD-1 detection (AUC=0.699, 95% CI 0.581-0.816, P=0.002). Conclusion:CD278 and PD-1 double positive expression serves as an important immunophenotypic marker for identifying AITL neoplastic cells, which enables detection of AITL cells with low proportions in bone marrow and peripheral blood.